Clinical trial
A Randomized Phase IIb Placebo-controlled Study of R-ICE Chemotherapy With and Without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-line Treatment of Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
NCT00529503 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase IIb Placebo-controlled Study of R-ICE Chemotherapy With and Without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-line Treatment of Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
- Lead sponsor
- Seagen Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- September 30, 2007
- Completion date
- May 31, 2011
- Enrollment
- 151 (actual)
- Sites
- 66
Conditions
As the registry lists them; a condition with its own page is linked.